Literature DB >> 33516459

Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer.

Yukio Watanabe1, Aritoshi Hattori1, Shuko Nojiri2, Takeshi Matsunaga1, Kazuya Takamochi1, Shiaki Oh1, Kenji Suzuki3.   

Abstract

OBJECTIVE: Non-small cell lung cancers with a ground-glass opacity component have better prognosis than those with solid nodules of equivalent consolidation size. However, the impact of small ground-glass opacity components on prognosis is unknown. Therefore, we aimed to evaluate the significance of a small ground-glass opacity component in solid-dominant clinical stage IA non-small cell lung cancers.
METHODS: We reviewed the cases of 543 surgically resected solid-dominant c-stage IA non-small cell lung cancers, which was defined as a tumor with consolidation tumor ratio of 0.75 or more on computed tomography. The patients were classified into 2 groups: 0.75 or less consolidation tumor ratio less than 1 (n = 126) and consolidation tumor ratio of 1 (n = 417). The prognoses were compared between the 2 groups.
RESULTS: Among the 543 cases, multivariable analyses revealed that pure-solid appearance was a predictor of worse overall survival (hazard ratio, 2.051; 95% confidence interval, 1.044-4.028). Compared with the part-solid group, the pure-solid group was associated with poor survival in c-stages IA2 (5-year overall survival: 91.5% vs 76.8%, hazard ratio, 2.942; 95% confidence interval, 1.402-6.173; recurrence-free survival: 89.0% vs 68.8%, hazard ratio, 3.439; 95% confidence interval, 1.776-6.669) and IA3 (5-year overall survival: 93.5% vs 63.0%, hazard ratio, 5.110; 95% confidence interval, 1.607-16.241; recurrence-free survival: 80.5% vs 54.1%, hazard ratio, 2.789; 95% confidence interval, 1.290-6.027). The T categories significantly affected 5-year overall survival only in the pure-solid group (cT1a, 89.3%; cT1b, 76.8%; cT1c, 63.0%).
CONCLUSIONS: A small ground-glass opacity component has an impact on the prognosis of patients with solid-dominant c-stage IA non-small cell lung cancer. Therefore, c-stage IA non-small cell lung cancers should be evaluated separately for tumors with ground-glass opacity and pure-solid tumors.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical stage IA; ground-glass opacity; non–small cell lung cancer; pure solid

Mesh:

Year:  2020        PMID: 33516459     DOI: 10.1016/j.jtcvs.2020.12.089

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Stapler-lavage cytology using a new rapid immunocytochemistry for evaluating surgical margin status after pulmonary sublobar resection.

Authors:  Nobuyasu Kurihara; Kazuhiro Imai; Shinogu Takashima; Hiroshi Nanjo; Yuko Hiroshima; Satoru Ito; Kyoko Nomura; Hajime Saito; Yoshihiro Minamiya
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-11-16

2.  Prognostic value of visceral pleural invasion in pure-solid and part-solid lung cancer patients.

Authors:  Satoru Okada; Aritoshi Hattori; Takeshi Matsunaga; Kazuya Takamochi; Shiaki Oh; Masayoshi Inoue; Kenji Suzuki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2020-09-12

3.  Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma.

Authors:  Masayuki Nakao; Katsunori Oikado; Yoshinao Sato; Kohei Hashimoto; Junji Ichinose; Yosuke Matsuura; Sakae Okumura; Hironori Ninomiya; Mingyon Mun
Journal:  JTO Clin Res Rep       Date:  2022-01-21

4.  Role of ground-glass opacity in pure invasive and lepidic component in pure solid lung adenocarcinoma for predicting aggressiveness.

Authors:  Takahiro Mimae; Yoshihiro Miyata; Yasuhiro Tsutani; Yoshihisa Shimada; Hiroyuki Ito; Haruhiko Nakayama; Norihiko Ikeda; Morihito Okada
Journal:  JTCVS Open       Date:  2022-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.